Guidant General Surgery Divestiture To USSC Represents Sales Of $40 Mil.
This article was originally published in The Gray Sheet
Executive Summary
Guidant's general surgery business, which will be sold to Tyco Healthcare Group's U.S. Surgical division under an agreement announced July 7, generated annual revenues of about $40 mil., analysts estimate.
You may also be interested in...
GSI Sole Supplier of Balloon Dissection Devices Following Guidant Injunction
General Surgical Innovations says it will be the sole supplier of balloon dissection-based devices for minimally invasive surgery in the U.S. effective Nov. 15, the result of an April 14 injunction against rival Origin Medsystems, a subsidiary of Guidant.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.